› Forums › General Melanoma Community › Sequential nivo then ipi = ORR of 41%. Ipi then nivo = 20%!!!
- This topic has 12 replies, 4 voices, and was last updated 9 years, 4 months ago by
Bubbles.
- Post
-
- September 28, 2015 at 2:13 am
As Weber alluded to in the webinar included in my last post…the synopsis thus far, of the CheckMate 064 trial with sequential Ipi followed by Nivo vs Nivo followed by Ipi was put out today at the 2015 European Cancer Congress.
Here is a post I put up that includes the abstract as well as a link to a report from OncLive. http://chaoticallypreciselifeloveandmelanoma.blogspot.com/2015/09/sequential-nivo-then-ipi-orr-of-41-ipi.htmlAll I can say is….Here's to the ratties. We owe you a debt of gratitude that we will never be able to repay.And……FDA…..Are you listening???????My best to you all. Celeste
- Replies
-
-
- September 28, 2015 at 1:45 pm
Impressive! This finding bears replication, of course, but it certainly says a lot about the FDA-sanctioned standards of treatment (ipi first).
My first thought is that I wonder how these results would compare to nivo alone. I suspect the nivo-first advantage relates to getting the more effective drug sooner, when it can do more good. Just a hunch.
-
- September 28, 2015 at 1:45 pm
Impressive! This finding bears replication, of course, but it certainly says a lot about the FDA-sanctioned standards of treatment (ipi first).
My first thought is that I wonder how these results would compare to nivo alone. I suspect the nivo-first advantage relates to getting the more effective drug sooner, when it can do more good. Just a hunch.
-
- September 28, 2015 at 1:45 pm
Impressive! This finding bears replication, of course, but it certainly says a lot about the FDA-sanctioned standards of treatment (ipi first).
My first thought is that I wonder how these results would compare to nivo alone. I suspect the nivo-first advantage relates to getting the more effective drug sooner, when it can do more good. Just a hunch.
-
- September 28, 2015 at 2:50 pm
Thanks for posting Celeste!!! This was a phase 2 trial of 160 patients which means a larger phase 3 trial will follow!!! The one thing that Melanoma continues to produce is ratties for big pharma Celeste, for at least the near future. My "mouse" study (checkmate 67) ends for me in January 2016 and I am sure that the data will support using Nivolumab first and the Nivo/Ipi combo as the standand for those who are healthy enough to tolerate the higher % chance of side effects that comes with the combo. Take care Ed!!!
-
- September 28, 2015 at 2:50 pm
Thanks for posting Celeste!!! This was a phase 2 trial of 160 patients which means a larger phase 3 trial will follow!!! The one thing that Melanoma continues to produce is ratties for big pharma Celeste, for at least the near future. My "mouse" study (checkmate 67) ends for me in January 2016 and I am sure that the data will support using Nivolumab first and the Nivo/Ipi combo as the standand for those who are healthy enough to tolerate the higher % chance of side effects that comes with the combo. Take care Ed!!!
-
- September 28, 2015 at 2:50 pm
Thanks for posting Celeste!!! This was a phase 2 trial of 160 patients which means a larger phase 3 trial will follow!!! The one thing that Melanoma continues to produce is ratties for big pharma Celeste, for at least the near future. My "mouse" study (checkmate 67) ends for me in January 2016 and I am sure that the data will support using Nivolumab first and the Nivo/Ipi combo as the standand for those who are healthy enough to tolerate the higher % chance of side effects that comes with the combo. Take care Ed!!!
- You must be logged in to reply to this topic.